Acquisition by Prudo-chlebosz Raymond of 419286000 shares of Akari Therapeutics at 0.0011 subject to Rule 16b-3
| AKTX Stock | USD 1.22 0.04 3.17% |
Slightly above 62% of Akari Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Akari Therapeutics PLC stock suggests that many investors are alarmed at this time. Akari Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Akari Therapeutics' earnings reports, geopolitical events, and overall market trends.
Akari |
Filed transaction by Akari Therapeutics PLC Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Akari Therapeutics Fundamental Analysis
We analyze Akari Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akari Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akari Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Akari Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Akari Therapeutics PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Akari Therapeutics stock to make a market-neutral strategy. Peer analysis of Akari Therapeutics could also be used in its relative valuation, which is a method of valuing Akari Therapeutics by comparing valuation metrics with similar companies.
Peers
Akari Therapeutics Related Equities
| PULM | Pulmatrix | 12.77 | ||||
| PCSA | Processa Pharmaceuticals | 4.29 | ||||
| SLRX | Salarius Pharmaceuticals | 1.87 | ||||
| SLNO | Soleno Therapeutics | 1.50 | ||||
| ANEB | Anebulo Pharmaceuticals | 1.86 | ||||
| ARMP | Armata Pharmaceuticals | 2.23 | ||||
| CAPR | Capricor Therapeutics | 2.48 | ||||
| SONN | Sonnet Biotherapeutics | 14.50 |
Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.